{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:37:50Z","timestamp":1791851870194,"version":"4.3.4"},"reference-count":64,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,5,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder. SMM is distinguished from monoclonal gammopathy of undetermined significance by a much higher risk of progression to multiple myeloma (MM). There have been major advances in the diagnosis, prognosis, and management of SMM in the last few years. These include a revised disease definition, identification of several new prognostic factors, a classification based on underlying cytogenetic changes, and new treatment options. Importantly, a subset of patients previously considered SMM is now reclassified as MM on the basis of biomarkers identifying patients with an \u226580% risk of progression within 2 years. SMM has assumed greater significance on the basis of recent trials showing that early therapy can be potentially beneficial to patients. As a result, there is a need to accurately diagnose and risk-stratify patients with SMM, including routine incorporation of modern imaging and laboratory techniques. In this review, we outline current concepts in diagnosis and risk stratification of SMM, and provide specific recommendations on the management of SMM.<\/jats:p>","DOI":"10.1182\/blood-2014-09-568899","type":"journal-article","created":{"date-parts":[[2015,4,3]],"date-time":"2015-04-03T08:55:46Z","timestamp":1428051346000},"page":"3069-3075","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":264,"title":["Smoldering multiple myeloma"],"prefix":"10.1182","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"first","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-4839","authenticated-orcid":false,"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[{"name":"Memorial Sloan-Kettering Cancer Center, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"25","key":"2019111818024222600_B1","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111818024222600_B2","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma.","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111818024222600_B3","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1001\/jama.2010.1713","article-title":"Multiple myeloma precursor disease.","volume":"304","author":"Landgren","year":"2010","journal-title":"JAMA"},{"issue":"9","key":"2019111818024222600_B4","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrclinonc.2012.128","article-title":"Haematological cancer: redefining myeloma.","volume":"9","author":"Rajkumar","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"2019111818024222600_B5","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111818024222600_B6","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/ajh.23204","article-title":"Preventive strategies in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.","volume":"87","author":"Rajkumar","year":"2012","journal-title":"Am J Hematol"},{"issue":"12","key":"2019111818024222600_B7","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"2019111818024222600_B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.seminhematol.2010.11.008","article-title":"Multiple myeloma precursor disease: current clinical dilemma and future opportunities.","volume":"48","author":"Landgren","year":"2011","journal-title":"Semin Hematol"},{"issue":"5","key":"2019111818024222600_B9","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMc1106428","article-title":"Diagnosis of smoldering multiple myeloma.","volume":"365","author":"Rajkumar","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111818024222600_B10","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2012.309","article-title":"Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease.","volume":"27","author":"Kastritis","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"2019111818024222600_B11","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"issue":"5s","key":"2019111818024222600_B12","article-title":"Modeling the risk of progression in smoldering multiple myeloma [abstract].","volume":"32","author":"Waxman","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111818024222600_B13","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.","volume":"28","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111818024222600_B14","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/leu.2014.230","article-title":"The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma.","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"2019111818024222600_B15","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S2352-3026(14)70001-8","article-title":"Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study.","volume":"1","author":"Kyle","year":"2014","journal-title":"Lancet Haematol"},{"issue":"13","key":"2019111818024222600_B16","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance.","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111818024222600_B17","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2014.34","article-title":"Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey.","volume":"28","author":"Landgren","year":"2014","journal-title":"Leukemia"},{"issue":"9727","key":"2019111818024222600_B18","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.","volume":"375","author":"Dispenzieri","year":"2010","journal-title":"Lancet"},{"issue":"18","key":"2019111818024222600_B19","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1056\/NEJMc1310911","article-title":"Treatment for high-risk smoldering myeloma.","volume":"369","author":"Kristinsson","year":"2013","journal-title":"N Engl J Med"},{"issue":"18","key":"2019111818024222600_B20","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1158\/1078-0432.CCR-09-1575","article-title":"Prevention of progression in monoclonal gammopathy of undetermined significance.","volume":"15","author":"Rajkumar","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2019111818024222600_B21","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2019111818024222600_B22","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/47.4.673","article-title":"Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine.","volume":"47","author":"Bradwell","year":"2001","journal-title":"Clin Chem"},{"issue":"9","key":"2019111818024222600_B23","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","article-title":"Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.","volume":"48","author":"Katzmann","year":"2002","journal-title":"Clin Chem"},{"issue":"9356","key":"2019111818024222600_B24","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(03)12457-9","article-title":"Serum test for assessment of patients with Bence Jones myeloma.","volume":"361","author":"Bradwell","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"2019111818024222600_B25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.","volume":"23","author":"Dispenzieri","year":"2009","journal-title":"Leukemia"},{"issue":"2","key":"2019111818024222600_B26","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111818024222600_B27","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2141.2003.04654.x","article-title":"Smoldering multiple myeloma: natural history and recognition of an evolving type.","volume":"123","author":"Rosi\u00f1ol","year":"2003","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111818024222600_B28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111818024222600_B29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2141.2009.07929.x","article-title":"Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells.","volume":"148","author":"P\u00e9rez-Persona","year":"2010","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111818024222600_B30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3324\/haematol.11080","article-title":"Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.","volume":"93","author":"Rawstron","year":"2008","journal-title":"Haematologica"},{"issue":"8","key":"2019111818024222600_B31","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma.","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"issue":"34","key":"2019111818024222600_B32","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.","volume":"31","author":"Neben","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111818024222600_B33","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/leu.2012.237","article-title":"High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma.","volume":"27","author":"Bianchi","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"2019111818024222600_B34","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1046\/j.1365-2141.1999.01244.x","article-title":"Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma.","volume":"104","author":"Mariette","year":"1999","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111818024222600_B35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.1995.13.1.251","article-title":"Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma.","volume":"13","author":"Moulopoulos","year":"1995","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111818024222600_B36","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4065\/mcp.2009.0653","article-title":"Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma.","volume":"85","author":"Madan","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"2019111818024222600_B37","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3109\/10428194.2013.764419","article-title":"Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study.","volume":"54","author":"Cherry","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2019111818024222600_B38","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"issue":"4","key":"2019111818024222600_B39","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2009.22.2257","article-title":"Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations.","volume":"28","author":"Blad\u00e9","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111818024222600_B40","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/leu.2014.75","article-title":"Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma.","volume":"28","author":"Merz","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2019111818024222600_B41","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.hoc.2014.06.005","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.","volume":"28","author":"Kyle","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"2019111818024222600_B42","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s11899-013-0174-1","article-title":"New approaches to smoldering myeloma.","volume":"8","author":"Mateos","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"issue":"26","key":"2019111818024222600_B43","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1182\/blood-2013-08-520890","article-title":"Smoldering multiple myeloma requiring treatment: time for a new definition?","volume":"122","author":"Dispenzieri","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111818024222600_B44","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nrclinonc.2013.160","article-title":"Haematological cancer: treatment of smoldering multiple myeloma.","volume":"10","author":"Rajkumar","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"2019111818024222600_B45","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I\u2014a randomized study.","volume":"50","author":"Hjorth","year":"1993","journal-title":"Eur J Haematol"},{"issue":"9","key":"2019111818024222600_B46","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/bjc.1996.212","article-title":"A prognostic index for multiple myeloma.","volume":"73","author":"Grignani","year":"1996","journal-title":"Br J Cancer"},{"issue":"7","key":"2019111818024222600_B47","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1054\/bjoc.1999.1087","article-title":"Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study.","volume":"82","author":"Riccardi","year":"2000","journal-title":"Br J Cancer"},{"issue":"1","key":"2019111818024222600_B48","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-2141.2002.03549.x","article-title":"Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect.","volume":"118","author":"Mart\u00edn","year":"2002","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111818024222600_B49","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3109\/10428194.2011.553000","article-title":"Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study.","volume":"52","author":"D\u2019Arena","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2019111818024222600_B50","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.","volume":"113","author":"Musto","year":"2008","journal-title":"Cancer"},{"issue":"4","key":"2019111818024222600_B51","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.leu.2402866","article-title":"Thalidomide as initial therapy for early-stage myeloma.","volume":"17","author":"Rajkumar","year":"2003","journal-title":"Leukemia"},{"issue":"1","key":"2019111818024222600_B52","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.","volume":"21","author":"Weber","year":"2003","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111818024222600_B53","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2008-06-164228","article-title":"Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019111818024222600_B54","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/leu.2012.236","article-title":"A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma.","volume":"27","author":"Witzig","year":"2013","journal-title":"Leukemia"},{"issue":"18","key":"2019111818024222600_B55","first-page":"1764","article-title":"Treatment for high-risk smoldering myeloma [letter to the editor].","volume":"369","author":"Dispenzieri","year":"2013","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111818024222600_B56","article-title":"Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRD-R) induces high rates of MRD negativity in newly diagnosed multiple myeloma (MM) patients [abstract].","volume":"122","author":"Zingone","year":"2013","journal-title":"Blood"},{"issue":"18","key":"2019111818024222600_B57","first-page":"1763","article-title":"Treatment for high-risk smoldering myeloma [letter to the editor].","volume":"369","author":"Tsuda","year":"2013","journal-title":"N Engl J Med"},{"issue":"18","key":"2019111818024222600_B58","first-page":"1764","article-title":"Treatment for high-risk smoldering myeloma [author reply].","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"issue":"18","key":"2019111818024222600_B59","first-page":"1764","article-title":"Treatment for high-risk smoldering myeloma [letter to the editor].","volume":"369","author":"Mahesh","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111818024222600_B60","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2014-01-548826","article-title":"Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed\/refractory multiple myeloma patients.","volume":"124","author":"Richardson","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019111818024222600_B61","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood-2014-01-548941","article-title":"Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma.","volume":"124","author":"Kumar","year":"2014","journal-title":"Blood"},{"issue":"16","key":"2019111818024222600_B62","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","article-title":"Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.","volume":"30","author":"Lonial","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111818024222600_B63","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1038\/bcj.2011.42","article-title":"The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies.","volume":"1","author":"van der Veer","year":"2011","journal-title":"Blood Cancer J"},{"issue":"14","key":"2019111818024222600_B64","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2013-05-484782","article-title":"Pomalidomide.","volume":"122","author":"Lacy","year":"2013","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/125\/20\/3069\/1385341\/3069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/125\/20\/3069\/1385341\/3069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T07:36:10Z","timestamp":1598859370000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/125\/20\/3069\/33942\/Smoldering-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,14]]},"references-count":64,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2015,5,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-09-568899","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725419665.793522184","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,14]]}}}